10 research outputs found
Glycoprotein IIb/IIIa inhibitors: Therapeutic applications in acute ST-segment elevation myocardial infarction
- Author
- Admiral Trial
- Antman
- Antman
- Bates
- Brenner
- Brodie
- Coller
- Collins
- Coulter
- E.Magnus Ohman
- Ellis
- Fibrinolytic Therapy Trialists' (FTT) Collaborative Group
- Fuster
- Gold
- Gold
- Grantham
- Greenbaum
- Herrmann
- Kevin R Campbell
- Kleiman
- Kleiman
- Kleiman
- Lefkovits
- Mahaffey
- Merkhof-van Den
- Michael Sketch
- Miller
- Neumann
- Ohman
- Ohman
- Ohman
- Ronner
- Stone
- The EPIC Investigators
- The GUSTO Angiographic Investigatiors
- The GUSTO IIb Angioplasty Substudy Investigators
- The GUSTO investigators
- The IMPACT-II Investigators
- The PARADIGM investigators
- The RESTORE Investigators
- Topol
- Warren Cantor
- Willerson
- Yasuda
- Publication venue
- 'Elsevier BV'
- Publication date
- Field of study
Recent trials of antithrombotics in the management of patients with acute coronary syndromes
- Author
- Publication venue
- 'Springer Science and Business Media LLC'
- Publication date
- Field of study
Prognostic importance of heart rate, and effect of sacubitril/valsartan according to heart rate, in PARADIGM-HF.
- Author
- Publication venue
- 'Wiley'
- Publication date
- 01/01/2016
- Field of study
Considerations in combination therapy: Fibrinolytics plus glycoprotein IIb/IIIa receptor inhibitors in acute myocardial infarction
- Author
- Antman
- Antman
- Antman
- Brener
- Cannon
- de Lemos
- Giugliano
- Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
- Kleiman
- Kong
- Ohman
- Ronner
- Ross
- Simoons
- Strategies for Patency Enhancement in the Emergency Department (SPEED) Group
- The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
- The EPIC Investigators
- The GUSTO Angiographic Investigators
- The PARADIGM Investigators
- Topol
- Topol
- Verheugt
- Publication venue
- 'Wiley'
- Publication date
- Field of study
Combination therapy for acute myocardial infarction: Glycoprotein ilb/iiia inhibitors plus thrombolysis
- Author
- Antman
- Antman
- Antman
- Bode
- Brener
- Cairns
- Cannon
- Cannon
- Cannon
- Coller
- Coller
- Davies
- Falk
- Ferguson
- Fuster
- Giugliano
- Gold
- Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)
- Gurbel
- iSIS-2 (Second International Study of Infarct Survival) Collaborative Group
- Ito
- Jang
- Kleiman
- Lefkovits
- Libby
- Lincoff
- Neumann
- Ohman
- Ohman EM Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, and the TAMI Study Group
- Owen
- Reverter
- Ronner
- Roux
- The CAPTURE Investigators
- The EPIC Investigators
- The EPILOG Investigators
- The EPISTENT Investigators
- The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators
- The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators
- The GUSTO Angiographic Investigators
- The IMPACT-II Investigators
- The PARADIGM Investigators
- The Platelet Inhibition for Ischemic Syndrome Management (PRISM) Study Investigators
- The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators
- The PURSUIT Trial Investigators
- The RESTORE Investigators
- The RISC Group
- Théroux
- Topol
- Topol
- Topol
- Van Belle
- Van de Werf
- Vaughan
- Weitz
- Yasuda
- Publication venue
- 'Wiley'
- Publication date
- Field of study
Gender differences in the effects of cardiovascular drugs
- Author
- American College of Cardiology/American Heart Association Task Force on Practice Guidelines
- American Heart Association Statistics Committee and Stroke Statistics Subcommittee
- Antithrombotic Trialists' Collaboration
- APPROVE Investigators
- ARISTOTLE Committees and Investigators
- ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic
- ATLAS ACS 2–TIMI 51 Investigators
- Authors/Task Force Members
- AVERROES Steering Committee and Investigators
- BEAUTIFUL Investigators
- Beta-Blockers in Heart Failure Collaborative Group
- Canadian Acute Coronary Syndrome Registry I and II Investigators
- Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
- Carvedilol Prospective Randomized Cumulative Survival Study Group
- CHAMPION PHOENIX Investigators
- CHARM Investigators and Committees
- Cholesterol Treatment Trialists' (CTT) Collaboration
- Collaboration Antithrombotic Trialists
- CRUSADE Investigators
- ENGAGE AF-TIMI 48 Investigators
- Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
- ESPRIT Investigators
- ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events) and TIMI (Thrombolysis in Myocardial Infarction) 11B Investigators
- EUGenMed Cardiovascular Clinical Study Group
- European Atherosclerosis Society Consensus Panel
- Fibrinolytic Therapy Trialists' (FTT) Collaborative Group
- Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators
- For the ACE inhibitor myocardial infarction collaborative group
- For the Amlodipine Cardiovascular Community Trial Study Group
- For the GUSTO-I Investigators
- For the HOT Study Group
- For the SWORD Investigators
- Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group
- Gruppo Italiano per lo Studio Della Streptochinasi nell'Infarto Miocardico (GISSI)
- Gusto V Investigators
- INITIATIVE Investigators
- Institute of Medicine (US) Committee on Women's Health Research Board on Population Health
- INTERHEART Study Investigators
- ISCOAT Study Group (Italian Study on Complications of Oral Anticoagulant Therapy)
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
- LIFE Study Group
- National Institutes of Health
- OASIS-6 Investigators
- OASIS-6 Trial Group
- Office of Extramural Research NIH
- OPTIMAAL Steering Committee of the OPTIMAAL Study Group
- PARADIGM-HF Committees Investigators
- PARADIGM-HF Investigators and Committees
- PLATO Investigators
- PLATO study group
- RE-LY Steering Committee and Investigators
- REMIT Investigators
- REPLACE-2 Investigators
- REPLACE-2 Investigators
- ROCKET AF Investigators
- SCAAR Study Group
- SHIFT Investigators
- SYNERGY Trial Investigators
- The GUSTO Investigators
- The Heart Outcomes Prevention Evaluation Study Investigators
- The MERIT-HF Study Group
- The SOLVD Investigattors
- TIMI 11A Investigators
- TRITON-TIMI 38 Investigators
- US General Accounting Office (GAO)
- VALIANT Investigators
- Valsartan Heart Failure Trial Investigators
- Valsartan in Acute Myocardial Infarction Trial Investigators
- VALUE Trial Group
- Women's Health Initiative Investigators
- Working Group on Thrombosis of the Italian Society of Cardiology
- Writing Group for the Women's Health Initiative Investigators
- Publication venue
- 'Oxford University Press (OUP)'
- Publication date
- Field of study
Risk of bleeding complications with antiplatelet agents: Meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials
- Author
- Antman
- Baigent
- Bergamasco
- Bertrand
- Blankenship
- Brener
- Buller
- Califf
- Cannon
- Cannon
- CAPRIE Steering Committee
- CAST Collaborative Group
- Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial
- CURE Investigators
- Diener
- EAFT (European Atrial Fibrillation Trial) Study Group
- EPILOG Investigators
- EPISTENT Investigators
- ESPRIT Investigators
- Gent
- Giugliano
- GUSTO IV-ACS Investigators
- Hansson
- Hass
- International Stroke Trial Collaborative Group
- Juul-Moller
- Kereiakes
- Leon
- Leon
- Lincoff
- Manson
- Moliterno
- Montalescot
- O'Neill
- Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
- Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
- Pulmonary Embolism Prevention (PEP) Trial Collaborative Group
- Rao
- RESTORE Investigators
- SALT Collaborative Group
- Scrutinio
- Second SYMPHONY Investigators
- Steering Committee of the Physicians' Health Study Research Group
- SYMPHONY Investigators
- Taylor
- Tcheng
- The Dutch TIA Trial Study Group
- The PARAGON Investigators
- Topol
- UK-TIA study group
- Urban
- Publication venue
- 'Wiley'
- Publication date
- 01/01/2003
- Field of study
Facilitated percutaneous coronary intervention: A novel concept in expediting and improving acute myocardial infarction care
- Author
- Antman
- Antman
- Antoniucci
- Brener
- Brener
- Brodie
- Cannon
- Cannon
- Cheitlin
- Davies
- de Lemos
- de Lemos
- de Lemos
- Every
- Fibrinolytic Therapy Trialists' (FTT) Collaborative Group
- Gawaz
- Gibbons
- Gibson
- Grines
- Grines
- Gruppo Italiano per lo Studio Della Sopravivenza nell'Infarto Miocardico
- Howard C Herrmann
- Ito
- Iwakura
- Karagounis
- Kleiman
- Krucoff
- Lange
- Lefer
- Lefkovits
- Lenderink
- Lincoff
- Lincoff
- L’Allier
- Matetsky
- Miller
- Montalscot
- Neumann
- Neumann
- Neumann
- Ohman
- Ohman
- O’Neill
- Robert H Li
- Ross
- Ross
- Ross
- Ryan
- Saito
- Schroder
- Shah
- Simes
- Simoons
- Strategies for Patency Enhancement in the Emergency Department (SPEED) Group
- SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group
- The EPIC Investigators
- The Global use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators
- The Global Use of Strategies to Open Occluded Coronary Arteries In Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators
- The GUSTO Angiographic Investigators
- The GUSTO Investigators
- The PARADIGM Investigators
- The Strategies for Patency Enhancement in the Emergency Department (SPEED) Group
- The TIMI Research Group
- TIMI Study Group
- Topol
- Weaver
- Ziljstra
- Publication venue
- 'Elsevier BV'
- Publication date
- Field of study
Reperfusion revisited: Beyond TIMI3 flow
- Author
- Abbo
- AIMS Trial Study Group
- Ambrosio
- Ambrosio
- Anderson
- Bolognese
- Bremerich
- Brochet
- Canet
- Choudhri
- Cobb
- Dietrich
- Dreyer
- El Maraghi
- Engler
- Flaherty
- Galiuto
- Gibson
- Go
- Iliceto
- Iliceto
- Ishihara
- Ito
- Ito
- Ito
- Ito
- Iwakura
- Jafar
- Jeremy
- Jolly
- Karagounis
- Kiyak
- Kleiman
- Kloner
- Kloner
- Kloner
- Knabb
- Kochanek
- Kondo
- Lenderink
- Lincoff
- Lincoff
- Mahaffey
- Minamino
- Myers
- Nakamura
- Neuhaus
- Neumann
- Neumann
- Obrenovitch
- Ohman
- Olafsson
- Piana
- Porter
- Przyklenk
- Ragosta
- Rawitscher
- Romson
- Ryan
- Saeed
- Saeed
- Saeed
- Sakata
- Sakuma
- Schofer
- Simes
- Taniyama
- The GUSTO II Investigators
- The GUSTO Investigators
- The PARADIGM Investigators
- TIMI Study Group
- Topol
- Topol
- Vanhaecke
- Vogt
- Wall
- Weaver
- Wilcox
- Wu
- Publication venue
- 'Wiley'
- Publication date
- Field of study
Glycoprotein IIb/IIIa Antagonists in the Setting of Rescue Percutaneous Coronary Intervention
- Author
- Antman EM
- Belenkie I
- Bode C
- Brener SJ
- Califf RM
- Coller BS
- Ellis SG
- Fuster V
- Gawaz M
- Gawaz M
- Gold HK
- Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).
- Harker LA
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
- Kleiman NS
- Lemos JA
- Lincoff AM
- Neumann F-J
- Ohman EM
- Ohman EM
- PARADIGM Investigators
- Ronner E
- Rothbaum DA
- Simoons ML
- Stone GW
- The ISIS-2 Collaborative Group.
- The RESTORE Investigators.
- The SPEED Group.
- Topol EJ
- Vermeer F
- Wilentz JR
- Publication venue
- 'Wiley'
- Publication date
- Field of study